Crispr Therapeutics AG (NASDAQ:CRSP) has been assigned an average recommendation of “Buy” from the nineteen ratings firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $70.86.
CRSP has been the topic of a number of recent research reports. BidaskClub raised Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Chardan Capital restated a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a research note on Monday, November 18th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research note on Tuesday, November 26th.
Shares of CRSP opened at $72.37 on Thursday. The firm has a fifty day simple moving average of $54.81 and a two-hundred day simple moving average of $47.38. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. As a group, analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Nikko Asset Management Americas Inc. increased its stake in shares of Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares in the last quarter. ARK Investment Management LLC raised its holdings in Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after acquiring an additional 121,176 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after acquiring an additional 116,540 shares in the last quarter. Finally, Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics in the third quarter worth about $21,167,000. Institutional investors and hedge funds own 49.81% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: How Do Mutual Funds Work?